{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:23:49Z","timestamp":1794799429901,"version":"4.9.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA215118"],"award-info":[{"award-number":["R01CA215118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA226926"],"award-info":[{"award-number":["R01CA226926"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276116"],"award-info":[{"award-number":["R01CA276116"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269213"],"award-info":[{"award-number":["R01CA269213"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA231630"],"award-info":[{"award-number":["U54CA231630"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DODCA230101"],"award-info":[{"award-number":["DODCA230101"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). Unfortunately, OT resistance has been reported in other cancers. Using preclinical mouse xenograft experiments, we show that OT effectively suppresses RMS growth, yet over half of RMS tumors develop resistance associated with transcriptomic changes that occur in the absence of recurrent genomic mutation. Importantly, most resistant RMS models upregulate the PIK3CA\/AKT pathway, activating NRF2 phosphorylation and subsequent transcriptional expression of multidrug resistance ABC transporters. PIK3CA inhibitor alpelisib re-sensitizes resistant cells to OT by suppressing expression of ABC transporters. The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA\/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.<\/jats:p>","DOI":"10.1038\/s41467-025-66632-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:43:00Z","timestamp":1765377780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The PIK3CA\/AKT pathway drives therapy resistance in rhabdomyosarcoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-5044","authenticated-orcid":false,"given":"Qiqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Corchete Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabateeshan","family":"Mathavarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Alpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-1344","authenticated-orcid":false,"given":"Priyanshu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Oultache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-3823","authenticated-orcid":false,"given":"Luca","family":"Pinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rheinbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-8318","authenticated-orcid":false,"given":"David M.","family":"Langenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"66632_CR1","doi-asserted-by":"crossref","first-page":"e27869","DOI":"10.1002\/pbc.27869","volume":"66","author":"ME Yohe","year":"2019","unstructured":"Yohe, M. E. et al. Insights into pediatric rhabdomyosarcoma research: challenges and goals. Pediatr. Blood Cancer 66, e27869 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"66632_CR2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1101\/gad.1545007","volume":"21","author":"DM Langenau","year":"2007","unstructured":"Langenau, D. M. et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21, 1382\u20131395 (2007).","journal-title":"Genes Dev."},{"key":"66632_CR3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216\u2013231 (2014).","journal-title":"Cancer Discov."},{"key":"66632_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2018.07.012","volume":"34","author":"E Stewart","year":"2018","unstructured":"Stewart, E. et al. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. Cancer Cell 34, 411\u2013426.e19 (2018).","journal-title":"Cancer Cell"},{"key":"66632_CR5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ccr.2013.11.002","volume":"24","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24, 710\u2013724 (2013).","journal-title":"Cancer Cell"},{"key":"66632_CR6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ng.2969","volume":"46","author":"S Kohsaka","year":"2014","unstructured":"Kohsaka, S. et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat. Genet. 46, 595\u2013600 (2014).","journal-title":"Nat. Genet."},{"key":"66632_CR7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PAS.0000000000000538","volume":"40","author":"R Alaggio","year":"2016","unstructured":"Alaggio, R. et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am. J. Surg. Pathol. 40, 224\u2013235 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"66632_CR8","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1002\/cam4.5211","volume":"12","author":"MT McEvoy","year":"2023","unstructured":"McEvoy, M. T. et al. Pediatric rhabdomyosarcoma incidence and survival in the United States: an assessment of 5656 cases, 2001-2017. Cancer Med. 12, 3644\u20133656 (2023).","journal-title":"Cancer Med."},{"key":"66632_CR9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/bjoc.2000.1273","volume":"83","author":"HA Cocker","year":"2000","unstructured":"Cocker, H. A., Pinkerton, C. R. & Kelland, L. R. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br. J. Cancer 83, 338\u2013345 (2000).","journal-title":"Br. J. Cancer"},{"key":"66632_CR10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00383-006-1852-z","volume":"23","author":"G Seitz","year":"2007","unstructured":"Seitz, G. et al. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr. Surg. Int. 23, 431\u2013439 (2007).","journal-title":"Pediatr. Surg. Int."},{"key":"66632_CR11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"66632_CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G. et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66632_CR13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.cell.2019.04.004","volume":"177","author":"C Yan","year":"2019","unstructured":"Yan, C. et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. Cell 177, 1903\u20131914.e14 (2019).","journal-title":"Cell"},{"key":"66632_CR14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago, A. F. et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 9, 1372\u20131387 (2019).","journal-title":"Cancer Discov."},{"key":"66632_CR15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","volume":"9","author":"E Stewart","year":"2014","unstructured":"Stewart, E. et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 9, 829\u2013841 (2014).","journal-title":"Cell Rep."},{"key":"66632_CR16","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5413-y","volume":"19","author":"P Lesueur","year":"2019","unstructured":"Lesueur, P. et al. Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer 19, 198 (2019).","journal-title":"BMC Cancer"},{"key":"66632_CR17","doi-asserted-by":"crossref","first-page":"203636132311523","DOI":"10.1177\/20363613231152333","volume":"15","author":"P Mahalingam","year":"2023","unstructured":"Mahalingam, P. et al. PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma. Rare Tumors 15, 20363613231152333 (2023).","journal-title":"Rare Tumors"},{"key":"66632_CR18","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","volume":"41","author":"M Ingham","year":"2023","unstructured":"Ingham, M. et al. Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250). J. Clin. Oncol. 41, 4154\u20134163 (2023).","journal-title":"J. Clin. Oncol."},{"key":"66632_CR19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"66632_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"66632_CR21","doi-asserted-by":"crossref","first-page":"eaax6367","DOI":"10.1126\/science.aax6367","volume":"368","author":"L Zandarashvili","year":"2020","unstructured":"Zandarashvili, L. et al. Structural basis for allosteric PARP-1 retention on DNA breaks. Science 368, eaax6367 (2020).","journal-title":"Science"},{"key":"66632_CR22","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"key":"66632_CR23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-18-0277","volume":"25","author":"DAR Heisey","year":"2019","unstructured":"Heisey, D. A. R. et al. The Ewing family of tumors relies on BCL-2 and BCL-X(L) to escape PARP inhibitor toxicity. Clin. Cancer Res. 25, 1664\u20131675 (2019).","journal-title":"Clin. Cancer Res."},{"key":"66632_CR24","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.3390\/ijms22115907","volume":"22","author":"CY Tsai","year":"2021","unstructured":"Tsai, C. Y. et al. NBM-BMX, an HDAC8 inhibitor, overcomes temozolomide resistance in glioblastoma multiforme by downregulating the beta-Catenin\/c-Myc\/SOX2 pathway and upregulating p53-mediated MGMT inhibition. Int. J. Mol. Sci. 22, 5907 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"66632_CR25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers12010098","volume":"12","author":"HH Lee","year":"2019","unstructured":"Lee, H. H. et al. Histone 2A family member J drives mesenchymal transition and temozolomide resistance in glioblastoma multiforme. Cancers (Basel) 12, 98 (2019).","journal-title":"Cancers (Basel)"},{"key":"66632_CR26","doi-asserted-by":"crossref","first-page":"101151","DOI":"10.1016\/j.drup.2024.101151","volume":"77","author":"Y Xue","year":"2024","unstructured":"Xue, Y. et al. CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer. Drug Resist. Updat 77, 101151 (2024).","journal-title":"Drug Resist. Updat"},{"key":"66632_CR27","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1634\/theoncologist.2019-0603","volume":"25","author":"A Valiakhmetova","year":"2020","unstructured":"Valiakhmetova, A. et al. Treatment of pediatric glioblastoma with combination olaparib and temozolomide demonstrates 2-year durable response. Oncologist 25, e198\u2013e202 (2020).","journal-title":"Oncologist"},{"key":"66632_CR28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235\u2013244 (2010).","journal-title":"Lancet"},{"key":"66632_CR29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2159-8290.CD-17-0935","volume":"8","author":"BJ Drapkin","year":"2018","unstructured":"Drapkin, B. J. et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Discov. 8, 600\u2013615 (2018).","journal-title":"Cancer Discov."},{"key":"66632_CR30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96\u2013100 (2017).","journal-title":"Nature"},{"key":"66632_CR31","doi-asserted-by":"crossref","first-page":"eabn1229","DOI":"10.1126\/sciadv.abn1229","volume":"8","author":"M Stanzione","year":"2022","unstructured":"Stanzione, M. et al. Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Sci. Adv. 8, eabn1229 (2022).","journal-title":"Sci. Adv."},{"key":"66632_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2019.00041","volume":"9","author":"P Daniel","year":"2019","unstructured":"Daniel, P. et al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front. Oncol. 9, 41 (2019).","journal-title":"Front. Oncol."},{"key":"66632_CR33","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-19-2000","volume":"26","author":"F Higuchi","year":"2020","unstructured":"Higuchi, F. et al. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin. Cancer Res. 26, 1690\u20131699 (2020).","journal-title":"Clin. Cancer Res."},{"key":"66632_CR34","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.21873\/invivo.12470","volume":"35","author":"K Hwang","year":"2021","unstructured":"Hwang, K. et al. The combination PARP inhibitor olaparib with temozolomide in an experimental glioblastoma model. Vivo 35, 2015\u20132023 (2021).","journal-title":"Vivo"},{"key":"66632_CR35","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.20.03060","volume":"39","author":"JF Shern","year":"2021","unstructured":"Shern, J. F. et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium. J. Clin. Oncol. 39, 2859\u20132871 (2021).","journal-title":"J. Clin. Oncol."},{"key":"66632_CR36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jmoldx.2010.11.010","volume":"13","author":"Z Su","year":"2011","unstructured":"Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74\u201384 (2011).","journal-title":"J. Mol. Diagn."},{"key":"66632_CR37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-11-2308","volume":"18","author":"V Nardi","year":"2012","unstructured":"Nardi, V. et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin. Cancer Res. 18, 1227\u20131236 (2012).","journal-title":"Clin. Cancer Res."},{"key":"66632_CR38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"66632_CR39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fmolb.2018.00086","volume":"5","author":"A Hervieu","year":"2018","unstructured":"Hervieu, A. & Kermorgant, S. The role of PI3K in met driven cancer: a recap. Front Mol. Biosci. 5, 86 (2018).","journal-title":"Front Mol. Biosci."},{"key":"66632_CR40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"66632_CR41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"66632_CR42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531\u2013538 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"66632_CR43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s43018-022-00414-w","volume":"3","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma. Nat. Cancer 3, 961\u2013975 (2022).","journal-title":"Nat. Cancer"},{"key":"66632_CR44","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.devcel.2022.04.003","volume":"57","author":"AG Patel","year":"2022","unstructured":"Patel, A. G. et al. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Dev. Cell 57, 1226\u20131240.e8 (2022).","journal-title":"Dev. Cell"},{"key":"66632_CR45","doi-asserted-by":"crossref","first-page":"eade9238","DOI":"10.1126\/sciadv.ade9238","volume":"9","author":"SG Danielli","year":"2023","unstructured":"Danielli, S. G. et al. Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Sci. Adv. 9, eade9238 (2023).","journal-title":"Sci. Adv."},{"key":"66632_CR46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38886-8","volume":"14","author":"J DeMartino","year":"2023","unstructured":"DeMartino, J. et al. Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma. Nat. Commun. 14, 3074 (2023).","journal-title":"Nat. Commun."},{"key":"66632_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50527-2","volume":"15","author":"SG Danielli","year":"2024","unstructured":"Danielli, S. G. et al. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nat. Commun. 15, 6307 (2024).","journal-title":"Nat. Commun."},{"key":"66632_CR48","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4161\/cc.20535","volume":"11","author":"GX Ruan","year":"2012","unstructured":"Ruan, G. X. & Kazlauskas, A. VEGF-A engages at least three tyrosine kinases to activate PI3K\/Akt. Cell Cycle 11, 2047\u20132048 (2012).","journal-title":"Cell Cycle"},{"key":"66632_CR49","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.cellbi.2008.07.007","volume":"32","author":"K Hamamura","year":"2008","unstructured":"Hamamura, K., Zhang, P. & Yokota, H. IGF2-driven PI3 kinase and TGFbeta signaling pathways in chondrogenesis. Cell Biol. Int. 32, 1238\u20131246 (2008).","journal-title":"Cell Biol. Int."},{"key":"66632_CR50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-021-00855-2","volume":"7","author":"QJ Gai","year":"2022","unstructured":"Gai, Q. J. et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct. Target Ther. 7, 33 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"66632_CR51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11011-023-01181-y","volume":"38","author":"S Fang","year":"2023","unstructured":"Fang, S. et al. Identification of the CCL2 PI3K\/Akt axis involved in autophagy and apoptosis after spinal cord injury. Metab. Brain Dis. 38, 1335\u20131349 (2023).","journal-title":"Metab. Brain Dis."},{"key":"66632_CR52","doi-asserted-by":"crossref","first-page":"e13001","DOI":"10.1111\/cpr.13001","volume":"54","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. CTGF facilitates cell-cell communication in chondrocytes via PI3K\/Akt signalling pathway. Cell Prolif. 54, e13001 (2021).","journal-title":"Cell Prolif."},{"key":"66632_CR53","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","volume":"39","author":"T Li","year":"2020","unstructured":"Li, T. et al. IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene 39, 2243\u20132257 (2020).","journal-title":"Oncogene"},{"key":"66632_CR54","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","volume":"21","author":"KH Kim","year":"2015","unstructured":"Kim, K. H. et al. SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491\u20131496 (2015).","journal-title":"Nat. Med."},{"key":"66632_CR55","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","volume":"34","author":"AB Iniguez","year":"2018","unstructured":"Iniguez, A. B. et al. Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling. Cancer Cell 34, 922\u2013938 e7 (2018).","journal-title":"Cancer Cell"},{"key":"66632_CR56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-22-1646","volume":"29","author":"KE Hebron","year":"2023","unstructured":"Hebron, K. E. et al. The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. Clin. Cancer Res. 29, 472\u2013487 (2023).","journal-title":"Clin. Cancer Res."},{"key":"66632_CR57","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-06-1344","volume":"67","author":"EF Petricoin","year":"2007","unstructured":"Petricoin, E. F. et al. Phosphoprotein pathway mapping: Akt\/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67, 3431\u20133440 (2007).","journal-title":"Cancer Res."},{"key":"66632_CR58","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00432-019-02851-0","volume":"145","author":"F Marampon","year":"2019","unstructured":"Marampon, F. et al. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. J. Cancer Res. Clin. Oncol. 145, 881\u2013893 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"66632_CR59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.neo.2014.05.005","volume":"16","author":"CP Irwin","year":"2014","unstructured":"Irwin, C. P. et al. PARPi-FL\u2013a fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia 16, 432\u2013440 (2014).","journal-title":"Neoplasia"},{"key":"66632_CR60","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2009-06-229443","volume":"115","author":"MG Kharas","year":"2010","unstructured":"Kharas, M. G. et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 115, 1406\u20131415 (2010).","journal-title":"Blood"},{"key":"66632_CR61","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/onc.2010.257","volume":"29","author":"A Chakrabarty","year":"2010","unstructured":"Chakrabarty, A. et al. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29, 5193\u20135203 (2010).","journal-title":"Oncogene"},{"key":"66632_CR62","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/1535-7163.MCT-10-0108","volume":"9","author":"A Singh","year":"2010","unstructured":"Singh, A. et al. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol. Cancer Ther. 9, 2365\u20132376 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"66632_CR63","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1007\/s11033-023-08384-7","volume":"50","author":"Z Sargazi","year":"2023","unstructured":"Sargazi, Z. et al. NFR2\/ABC transporter axis in drug resistance of breast cancer cells. Mol. Biol. Rep. 50, 5407\u20135414 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"66632_CR64","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05044-9","volume":"13","author":"I de Souza","year":"2022","unstructured":"de Souza, I. et al. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation. Cell Death Dis. 13, 591 (2022).","journal-title":"Cell Death Dis."},{"key":"66632_CR65","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1093\/nar\/gks409","volume":"40","author":"BN Chorley","year":"2012","unstructured":"Chorley, B. N. et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 40, 7416\u20137429 (2012).","journal-title":"Nucleic Acids Res."},{"key":"66632_CR66","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1093\/nar\/gkq212","volume":"38","author":"D Malhotra","year":"2010","unstructured":"Malhotra, D. et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718\u20135734 (2010).","journal-title":"Nucleic Acids Res."},{"key":"66632_CR67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ebiom.2019.08.037","volume":"48","author":"M Zhan","year":"2019","unstructured":"Zhan, M. et al. Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer. EBioMedicine 48, 143\u2013160 (2019).","journal-title":"EBioMedicine"},{"key":"66632_CR68","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.29040","volume":"136","author":"B Gobin","year":"2015","unstructured":"Gobin, B. et al. BYL719, a new alpha-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int. J. Cancer 136, 784\u2013796 (2015).","journal-title":"Int. J. Cancer"},{"key":"66632_CR69","volume":"10","author":"KJ Kim","year":"2020","unstructured":"Kim, K. J. et al. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Sci. Rep. 10, 12308 (2020).","journal-title":"Sci. Rep."},{"key":"66632_CR70","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-01320-8","volume":"22","author":"NA O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, N. A. et al. Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 22, 89 (2020).","journal-title":"Breast Cancer Res."},{"key":"66632_CR71","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. The PI3K subunits, P110alpha and P110beta are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol. Cancer 19, 10 (2020).","journal-title":"Mol. Cancer"},{"key":"66632_CR72","volume":"21","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol. Cancer 21, 103 (2022).","journal-title":"Mol. Cancer"},{"key":"66632_CR73","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3390\/molecules26113157","volume":"26","author":"T Farkhondeh","year":"2021","unstructured":"Farkhondeh, T. et al. Roles of Nrf2 in gastric cancer: targeting for therapeutic strategies. Molecules 26, 3157 (2021).","journal-title":"Molecules"},{"key":"66632_CR74","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/cancers11111755","volume":"11","author":"AA Zimta","year":"2019","unstructured":"Zimta, A. A. et al. The role of Nrf2 activity in cancer development and progression. Cancers (Basel) 11, 1755 (2019).","journal-title":"Cancers (Basel)"},{"key":"66632_CR75","first-page":"117","volume":"41","author":"A Citti","year":"2012","unstructured":"Citti, A. et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. Int. J. Oncol. 41, 117\u2013124 (2012).","journal-title":"Int. J. Oncol."},{"key":"66632_CR76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega, M., Chapman, E. & Zhang, D. D. NRF2 and the Hallmarks of Cancer. Cancer Cell 34, 21\u201343 (2018).","journal-title":"Cancer Cell"},{"key":"66632_CR77","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross, D. A. et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995).","journal-title":"Nature"},{"key":"66632_CR78","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ncb3341","volume":"18","author":"EC Lien","year":"2016","unstructured":"Lien, E. C. et al. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K\/Akt-driven breast cancer. Nat. Cell Biol. 18, 572\u2013578 (2016).","journal-title":"Nat. Cell Biol."},{"key":"66632_CR79","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","volume":"1865","author":"I Bellezza","year":"2018","unstructured":"Bellezza, I. et al. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim. Biophys. Acta Mol. Cell Res. 1865, 721\u2013733 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"66632_CR80","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopha.2017.10.129","volume":"97","author":"F Jeddi","year":"2018","unstructured":"Jeddi, F. et al. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed. Pharmacother. 97, 286\u2013292 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"66632_CR81","doi-asserted-by":"crossref","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","volume":"25","author":"G Canaud","year":"2023","unstructured":"Canaud, G. et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet. Med. 25, 100969 (2023).","journal-title":"Genet. Med."},{"key":"66632_CR82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","volume":"30","author":"S Singh","year":"2024","unstructured":"Singh, S. et al. FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin. Cancer Res. 30, 23\u201328 (2024).","journal-title":"Clin. Cancer Res."},{"key":"66632_CR83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/hupa.2003.10","volume":"34","author":"JW Klunder","year":"2003","unstructured":"Klunder, J. W. et al. Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum. Pathol. 34, 150\u2013155 (2003).","journal-title":"Hum. Pathol."},{"key":"66632_CR84","first-page":"755","volume":"26","author":"C Melguizo","year":"2011","unstructured":"Melguizo, C. et al. Multidrug resistance and rhabdomyosarcoma (Review). Oncol. Rep. 26, 755\u2013761 (2011).","journal-title":"Oncol. Rep."},{"key":"66632_CR85","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.ATV.0000110502.10593.06","volume":"24","author":"MR Abid","year":"2004","unstructured":"Abid, M. R. et al. Vascular endothelial growth factor activates PI3K\/Akt\/forkhead signaling in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 294\u2013300 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"66632_CR86","volume":"13","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK\/ERK and PI3K\/Akt signaling routes. Breast Cancer Res. 13, R52 (2011).","journal-title":"Breast Cancer Res."},{"key":"66632_CR87","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1038\/onc.2011.97","volume":"30","author":"Y Su","year":"2011","unstructured":"Su, Y. et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 30, 3907\u20133917 (2011).","journal-title":"Oncogene"},{"key":"66632_CR88","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2012.85","volume":"106","author":"A Gallardo","year":"2012","unstructured":"Gallardo, A. et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br. J. Cancer 106, 1367\u20131373 (2012).","journal-title":"Br. J. Cancer"},{"key":"66632_CR89","first-page":"4151","volume":"70","author":"JH Dey","year":"2010","unstructured":"Dey, J. H. et al. Targeting fibroblast growth factor receptors blocks PI3K\/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70, 4151\u20134162 (2010).","journal-title":"Cancer Res."},{"key":"66632_CR90","doi-asserted-by":"crossref","first-page":"e63404","DOI":"10.1371\/journal.pone.0063404","volume":"8","author":"L Ji","year":"2013","unstructured":"Ji, L. et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS ONE 8, e63404 (2013).","journal-title":"PLoS ONE"},{"key":"66632_CR91","first-page":"149","volume":"555","author":"P Nioi","year":"2004","unstructured":"Nioi, P. & Hayes, J. D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555, 149\u2013171 (2004).","journal-title":"Mutat. Res."},{"key":"66632_CR92","doi-asserted-by":"crossref","unstructured":"Remy, A. et al. Fixed dosing of alpelisib for children with vascular anomalies: can we do better? Br. J. Clin. Pharmacol. 91, 914\u2013920 (2025).","DOI":"10.1111\/bcp.16388"},{"key":"66632_CR93","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 20, 570\u2013580 (2019).","journal-title":"Lancet Oncol."},{"key":"66632_CR94","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/emmm.201000070","volume":"2","author":"D Dias-Santagata","year":"2010","unstructured":"Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146\u2013158 (2010).","journal-title":"EMBO Mol. Med."},{"key":"66632_CR95","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S. et al. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"66632_CR96","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589\u2013595 (2010).","journal-title":"Bioinformatics"},{"key":"66632_CR97","doi-asserted-by":"crossref","first-page":"i172","DOI":"10.1093\/bioinformatics\/bts236","volume":"28","author":"T Conway","year":"2012","unstructured":"Conway, T. et al. Xenome\u2013a tool for classifying reads from xenograft samples. Bioinformatics 28, i172\u2013i178 (2012).","journal-title":"Bioinformatics"},{"key":"66632_CR98","doi-asserted-by":"crossref","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).","journal-title":"Gigascience"},{"key":"66632_CR99","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","volume":"31","author":"A Tarasov","year":"2015","unstructured":"Tarasov, A. et al. Sambamba: fast processing of NGS alignment formats. Bioinformatics 31, 2032\u20132034 (2015).","journal-title":"Bioinformatics"},{"key":"66632_CR100","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E. et al. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"66632_CR101","doi-asserted-by":"crossref","unstructured":"Qi, M. et al. Loss of chromosome Y in primary tumors. Cell 186, 3125\u20133136 (2023).","DOI":"10.1016\/j.cell.2023.06.006"},{"key":"66632_CR102","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"66632_CR103","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"66632_CR104","doi-asserted-by":"crossref","DOI":"10.1186\/s13029-016-0060-z","volume":"11","author":"M Riester","year":"2016","unstructured":"Riester, M. et al. PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code Biol. Med. 11, 13 (2016).","journal-title":"Source Code Biol. Med."},{"key":"66632_CR105","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","volume":"32","author":"ZL Skidmore","year":"2016","unstructured":"Skidmore, Z. L. et al. GenVisR: genomic visualizations in R. Bioinformatics 32, 3012\u20133014 (2016).","journal-title":"Bioinformatics"},{"key":"66632_CR106","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"66632_CR107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"66632_CR108","doi-asserted-by":"crossref","first-page":"D810","DOI":"10.1093\/nar\/gkn798","volume":"37","author":"MK Shimada","year":"2009","unstructured":"Shimada, M. K. et al. VarySysDB: a human genetic polymorphism database based on all H-InvDB transcripts. Nucleic Acids Res. 37, D810\u2013D815 (2009).","journal-title":"Nucleic Acids Res."},{"key":"66632_CR109","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/prca.200900045","volume":"3","author":"MJ Kennedy","year":"2009","unstructured":"Kennedy, M. J. et al. Urine collected from diapers can be used for 2-D PAGE in infants and young children. Proteom. Clin. Appl. 3, 989\u2013999 (2009).","journal-title":"Proteom. Clin. Appl."},{"key":"66632_CR110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"66632_CR111","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"66632_CR112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"66632_CR113","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66632-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66632-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66632-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:04:07Z","timestamp":1767679447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66632-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66632"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66632-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}